Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase NA 1Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 1Neoplasms 1Clear-cell metastatic renal cell carcinoma 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Radiopharmaceuticals × Clear all
NCT07567521 2026-05-29

A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC

C Ray Therapeutics

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Prostatic Neoplasms

NCT06059014 2026-04-24

PRadR

Centre Leon Berard

Phase 1/2 Completed
6 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma

NCT04538950 2023-09-13

PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy

Mayo Clinic

Phase 1/2 Completed
6 enrolled 6 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡